We found that ESR1 gene amplification was specifically selected in patients treated with adjuvant AI- and/or LHRHa-based therapy, thus suggesting that it could be a novel mechanism of tumor resistance to ET in HR+ HER2- BC beyond the more studied and previously characterized ESR1 mutations [5,6,30–33]. Here, ERBB2 is linked to neoplasm.